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Objective To evaluate the association between deferred delivery in
early-onset pre-eclampsia and offspring outcome and maternal
cardiovascular, renal and metabolic function in the postpartum
period.
Design Observational study.
Setting Tertiary referral hospital.
Population Nulliparous women diagnosed with pre-eclampsia
before 34 weeks’ gestation who participated in a routine
postpartum cardiovascular risk assessment programme. Women
with hypertension, diabetes mellitus or renal disease prior to
pregnancy were excluded.
Methods Regression analyses were performed to assess the
association between pregnancy prolongation and outcome
measures.
Main outcome measures Offspring outcome and prevalence of
deviant maternal cardiovascular, renal and metabolic function.
Results The study population included 564 women with a
median pregnancy prolongation of 10 days (interquartile range
[IQR] 4–18) who were assessed at on average 8 months (IQR
6–12) postpartum. Pregnancy prolongation after diagnosis
resulted in a decrease in infant mortality (adjusted odd ratio
[aOR] 0.907, 95% CI 0.852–0.965 per day prolongation). This
improvement in offspring outcome was associated with an
elevated risk of moderately increased albuminuria (aOR 1.025,
95% CI 1.006–1.045 per day prolongation), but not with
aberrant cardiac geometry, cardiac systolic or
diastolic dysfunction, persistent hypertension or metabolic
syndrome.
Conclusion Pregnancy prolongation in early-onset pre-eclampsia is
associated with improved offspring outcome and survival. These
effects do not appear to be deleterious to short-term maternal
cardiovascular and metabolic function but are associated with a
modest increase in risk of residual albuminuria.
Keywords Albuminuria, cardiovascular health, deferred delivery,
early-onset pre-eclampsia, hypertension, metabolic syndrome.
Tweetable abstract Pregnancy prolongation in pre-eclampsia has
only a limited effect on postpartum maternal cardiovascular
function.
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Introduction
Pre-eclampsia, a gestational hypertensive disorder, substan-
tially increases maternal and offspring morbidity and mor-
tality.1 It is thought to be an endothelial disease where
pathogenesis involves suboptimal placental function and
cardiovascular maladaptation, mostly superimposed upon
subclinical pre-existing cardiovascular and metabolic risk
factors.2,3 Forty percent of women with preterm pre-
eclampsia have asymptomatic structural cardiac alterations
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or dysfunction at 1 year postpartum, and within 15 years
after delivery, pre-eclampsia relates to a two- to seven-fold
increased risk of coronary heart disease, stroke and related
death and a four-fold increased risk of end-stage renal dis-
ease.4,5 Hypertension is prevalent in 25% of women within
a few years after pregnancy and up to 20% of women meet
the criteria for metabolic syndrome by that time.4,6 It is
not evident whether the postpartum sequelae are a conse-
quence of the pre-existing underlying maternal cardiovas-
cular risk factors or due to the deleterious effects of the
gestational disease itself on the maternal cardiovascular sys-
tem.7–9
Delivery is currently the only definite treatment of pre-
eclampsia and scheduled delivery is clinically dependent on
gestation at diagnosis, severity of maternal disease and fetal
condition. This decision often presents a management
dilemma because premature birth increases the risk of
neonatal morbidity and mortality, whereas expectant man-
agement increases maternal jeopardy from deterioration of
the pre-eclamptic condition.10 International guidelines gen-
erally recommend expectant management with continued,
vigilant surveillance of mother and fetus, with scheduled
delivery for features of severe maternal disease or signs of
fetal compromise.11,12 Risk of maternal peripartum compli-
cations can be estimated by the PIERS model, which pre-
dicts adverse maternal outcomes based on a few parameters
that are readily obtainable in clinical practice.13
Prolongation of pregnancy by a week in women with
gestational hypertensive disorders at term did not relate to
increased prevalence of metabolic syndrome.14 However, it
does seem to be associated with persistence of postpartum
hypertension and with the risk of severe cardiovascular dis-
eases, suggesting that prolonged exposure to pre-eclampsia
affects remote maternal cardiovascular health.15,16 There is
a real paucity of evidence on the effect of expectant man-
agement of severe, early-onset pre-eclampsia on postpar-
tum maternal cardiovascular recovery and function. The
objective of this observational study was to evaluate the
association between duration of gestational disease expo-
sure and offspring outcome and maternal cardiovascular,
renal and metabolic function in primiparous women.
Material and methods
Study population
There were no patients involved, or public involvement in
the design and conduct of this research. No core outcome
set has been used. Informed consent related to the use of
clinically acquired data for scientific analysis was obtained
as is customary in the Maastricht University Medical Cen-
tre (MUMC). From 1996, postpartum assessment was
offered to all women with pre-eclampsia and related com-
plications during pregnancy. The clinical service was
accessible to all women in the country and approximately
65% of women were referred by physicians from other hos-
pitals, who mainly refer women with severe complications
during their pregnancy. The assessment took place at least
4, but preferably 6 months postpartum, and women were
only scheduled when not breastfeeding to measure plasma
volume by the Iodine125 albumin indicator dilution tech-
nique (not evaluated in this study). For our analysis, we
included only women admitted to the assessment within
2 years after delivery, and with onset of pre-eclampsia
before 34 weeks’ gestation, as in these women, pregnancy
prolongation is assumed to benefit offspring outcome.
General management of these women was according to
international guidelines, recommending a temporising
management plan in women without features of severe dis-
ease, and an individualised approach in women with fea-
tures of severe disease. Women who presented with pre-
eclampsia before 24 weeks were excluded, as expectant
management was not typically offered as a standard treat-
ment option.17 Women who presented with stillbirth at the
time of admission were excluded, as the clinical considera-
tion of whether to terminate pregnancy for the benefit of
the fetus is no longer an issue. Multiparous women and
women with pre-pregnancy hypertension, diabetes mellitus
or renal disease were also excluded.
Postpartum assessment
Assessment of cardiovascular, renal and metabolic risk fac-
tors was performed in standardised conditions at a morn-
ing clinic after an overnight fast. Clinical data on obstetric
history, medical history and use of medication were col-
lected from medical files, referral letters and direct patient
enquiry. Diagnosis of pre-eclampsia was taken as the gesta-
tional age at which hypertension and proteinuria were
observed for the first time. Glucose, insulin, creatinine and
lipid-spectrum levels were obtained from fasting blood
samples. Urine was collected in the 24 hours preceding the
measurements and was assayed for albumin, creatinine and
total protein. Body mass index [BMI] was calculated by
dividing the bodyweight in kilograms by the squared height
in meters. Arterial blood pressure was measured in sitting
position by a semiautomatic oscillometric device (Dinamap
Vital Signs Monitor 1846; Critikon, Tampa, FL, USA) every
3 minutes. The median value of 11 measurements was
reported. Transthoracic echocardiography was performed
according to the American Society of Echocardiography
(ASE) guidelines using a commercially available phased-ar-
ray echocardiographic Doppler system (iE33 system with
S5-1 or X5-1 transducers, Philips Medical Systems, Best,
Netherlands).18 All images were acquired in left lateral
position, recorded as ECG-gated digital loops and stored
for off-line analysis. Using M-mode in the parasternal
long-axis view, we measured left ventricular end-diastolic
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(LVEDd) and end-systolic (LVESd) diameters, end-diastolic
interventricular septum thickness (IVST) and the posterior
(inferolateral) wall thickness (PWT). As recommended by
the ASE, left ventricular mass (LVM; g) was determined
using the Devereux formula: 0.8 9 {1.04 ([LVEDd +
PWT + IVST]3 – [LVEDd]3) + 0.6}, indexed for body sur-
face area.19,20 Relative wall thickness (RWT) was computed
using the formula: 2 9 PWT/LVEDd.20 Left ventricular
end-diastolic (EDV) and end-systolic volumes (ESV) were
determined using the Teichholz formula. Left ventricular
ejection fraction (%) was calculated using the formula:
([EDV-ESD]/EDV) 9 100.
Definitions
Pre-eclampsia was defined as new-onset hypertension with
a systolic blood pressure ≥140 mmHg and/or diastolic
blood pressure ≥90 mmHg in two repeated measurements
along with de novo proteinuria (≥0.3 g/24 hours or ≥2+
on dipstick analysis) after 20 weeks’ gestation. Early-onset
pre-eclampsia was defined as diagnosis before 34 weeks’
gestation. HELLP syndrome was defined as haemolysis
(LDH >600 U/l), elevated liver enzymes (AST and ALT >70
U/L) and low platelets (platelet count <100.109/l). Small-
for-gestational-age (SGA) birth was defined as neonatal
birthweight below the 10th percentile of the national birth-
weight charts, corrected for sex of the neonate and parity.21
Infant mortality was defined as death within 1 year after
delivery.
Cardiac systolic dysfunction was defined as an ejection
fraction ≤55% and aberrant cardiac geometry was defined by
left ventricular mass index >95 g/m2, or RWT >0.42. Kidney
function was evaluated based on the Kidney Disease Improv-
ing Global Outcomes (KDIGO) criteria, indicating that
monitoring of kidney function at least once a year is required
for women with a glomerular filtration rate <60 ml/minute/
1.73 m2 or an albumin-to-creatinine ratio ≥3.0 g/mol
creatinine.22
Constituents of the metabolic syndrome were defined based
on World Health Organization criteria as follows: hyperinsu-
linemia (fasting insulin >9.2 mU/l, fasting glucose >6.1 mmol/
l, and/or homeostasis model assessment for insulin resistance
[HOMA-IR] >2.2), obesity (BMI >30 kg/m2), dyslipidaemia
(triglycerides ≥1.7 mmol/l or HDL-cholesterol <0.9 mmol/l),
hypertension (systolic blood pressure ≥ 140 mmHg, diastolic
blood pressure ≥ 90 mmHg and/or the use of antihypertensive
medication) and proteinuria (albuminuria >2.5 g/mol crea-
tinine or proteinuria >0.30 g/24 h).23 Metabolic syndrome was
defined as hyperinsulinemia along with two or more of the
other constituents.
Statistical analysis
Women were divided into three groups based on duration
of pre-eclampsia to give a general insight in the study
population characteristics. Trends in difference between
groups were analysed with pregnancy prolongation in days
between diagnosis and delivery as a continuous variable,
and not categorically. Logistic and linear regression analy-
sis, whenever applicable, was performed to estimate the
associations between duration of pre-eclampsia and off-
spring outcome, and maternal deviant cardiovascular, renal
and metabolic function. Because postpartum time intervals
could differ between women, we corrected for time-interval
between delivery and postpartum assessment by adding
time as a covariate in the multivariable regression analysis
when analysing the maternal effects. In addition, adjusted
odds ratios (aOR) were calculated with multivariable regres-
sion analysis. We adjusted for gestational age at delivery,
maternal age, year of assessment and the presence of meta-
bolic syndrome factors at evaluation. A two-sided P-value of
0.05 or below was considered statistically significant. All sta-
tistical analyses were performed using IBM SPSS Statistics
version 24.0 (IBM Corp., Armonk, NY, USA).
Results
Between September 1996 and July 2018, 709 women with a
history of early-onset pre-eclampsia were admitted to the
MUMC for postpartum cardiovascular and metabolic risk
assessment (Figure 1). Selecting primiparous women with-
out pre-existing diseases resulted in 594 eligible women.
Characteristics of women with onset of pre-eclampsia
before 24 weeks’ gestation (n = 23) or who presented with
stillbirth (n = 7) are presented in Table S1. In the analysis
were 564 women whose obstetric characteristics are pre-
sented in Table 1. Median pregnancy prolongation was
10 days, gestational age at diagnosis was lower in the group
of women with the longest pregnancy prolongation, and
prevalence of HELLP syndrome was highest in the group
with short pregnancy prolongation.
Postpartum maternal status
Regression analysis showed no differences in postpartum car-
diac geometry and function, vascular function, renal function
or metabolic syndrome components with pregnancy prolon-
gation (Tables 2 and S2). The OR adjusted for the interval
between delivery and postpartum assessment showed that
pregnancy prolongation was associated with moderately
increased postpartum albuminuria (OR 1.022, 95% CI 1.005–
1.040 per day prolongation) but not with severely increased
proteinuria (Table 3). After adjustments for gestational age at
delivery, maternal age, year of postpartum assessment and
metabolic syndrome constituents, the association with mod-
erately increased albuminuria persisted. Pregnancy prolonga-
tion was not associated with reduced creatinine clearance,
annual monitoring of kidney function advice, deviant cardiac
parameters or hypertension postpartum.
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Offspring outcome
There were no offspring outcomes associated with pregnancy
prolongation, apart from higher absolute birthweight in
women whose pregnancy was prolonged longer (Table 1).
Pregnancy prolongation did not increase the risk of placental
abruption, stillbirth or prevalence of SGA neonates but was
associated with a significant decrease in infant mortality (OR
0.952, 95% CI 0.909–0.998) (Table S3). When adjusted for
gestational age at diagnosis, concurrent HELLP syndrome
and eclampsia, and year of assessment, the beneficial effect of
pregnancy prolongation on infant survival persisted (aOR
0.907, 95% CI 0.852–0.965).
Discussion
Main findings
This observational study demonstrates that pregnancy pro-
longation in early-onset pre-eclampsia is related to
improved offspring outcome and survival but is not associ-
ated with deleterious effects on maternal cardiovascular,
renal and metabolic function in the postpartum period,
other than an increased risk of moderately increased albu-
minuria.
Strengths and limitations
The strength of our study is the extensive postpartum
assessment of risk factors, which enabled us to correct for
cardiovascular and renal risk factors. Some limitations also
need to be addressed. Firstly, detailed information on anti-
hypertensive treatment, target blood pressure and other
Women admied for 
postpartum assessment aer 
early-onset preeclampsia 
within two years aer 
delivery 
(1996 - 2018)
n = 709
Primiparous women 
n = 665
Women with pre-exisng 
hypertension, diabetes 
mellitus or renal disease 
prior to pregnancy
n = 71
Mulparous women 
n = 44
Eligible women
n = 594
Women with onset of 
preeclampsia before 24 
weeks (n = 23), and women 
who presented with 
sllbirth (n = 7)
Women included in analysis
n = 564
Figure 1. Flowchart for selection of women.
Table 1. Obstetric characteristics of study population categorised by duration of pregnancy prolongation
Pregnancy outcome Total Pregnancy prolongation P-value*
≤6 days 7–13 days ≥14 days
n = 564 n = 186 n = 173 n = 205
Prolongation in days 10 [4–18] 3 [1–4] 9 [7–11] 21 [17–30]
GA at diagnosis 300 [280–320] 310 [290–325] 300 [280–320] 300 [270–320] <0.001
GA at delivery 320 [295–336] 315 [292– 331] 312 [290–330] 330 [305–351] <0.001
HELLP syndrome 404/564 (72%) 134/186 (72%) 131/173 (76%) 139/205 (68%) 0.017
Eclampsia 34/564 (6%) 17/186 (9%) 5/173 (3%) 13/205 (6%) 0.690
Birthweight, g 1400 [1000–1810] 1348 [975–1677] 1270 [875–1680] 1620 [1165–2060] <0.001
Birthweight centile 16 [8–30] 18 [8–32] 16 [8–25] 15 [8–31] 0.805
Multifetal pregnancy 20/564 (4%) 7/186 (4%) 5/173 (3%) 8/205 (4%) 0.936
SGA birth/neonate 179/564 (32%) 54/186 (29%) 55/173 (32%) 70/205 (34%) 0.255
Placental abruption 19/564 (3%) 10/186 (5%) 5/173 (3%) 4/205 (2%) 0.109
Offspring demise 36/564 (6%) 15/186 (8%) 13/173 (8%) 8/205 (4%) 0.036
Stillbirth 8/564 (1%) 2/186 (1%) 4/173 (2%) 2/205 (1%) 0.559
Infant mortality 28/564 (5%) 13/186 (7%) 9/173 (5%) 6/205 (2%) 0.042
GA, gestational age; SGA, small for gestational age.
Data are presented as median [interquartile range], or number/known outcome (percentage in group).
*P-value indicates trend based on regression analysis with pregnancy prolongation used as a continuous variable.
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Table 2. Pregnancy prolongation and postpartum maternal cardiovascular, renal and metabolic function
Total ≤6 days 7–13 days ≥14 days P-value*
n = 564 n = 186 n = 173 n = 205
Time to assessment (months) 8 [6–12] 8 [6–12] 7 [6–12] 8 [6–14] 0.006
Maternal age (years) 30.4 (4.2) 29.9 (4.0) 30.6 (4.1) 30.8 (4.5) 0.090
Cardiac parameters
LVM index (g/m2) 70 [61–79] 69 [61–79] 69 [60–78] 71 [61–80] 0.916
Relative wall thickness 0.33 [0.30–0.35] 0.33 [0.30–0.35] 0.32 [0.30–0.35] 0.33 [0.30–0.35] 0.698
Ejection fraction (%) 64 [61–67] 64 [61–67] 64 [60–67] 64 [60–67] 0.861
Renal parameters
Albuminuria (g/mol creatinine) 1.0 [0.5–2.3] 0.8 [0.4–1.9] 1.0 [0.6–2.2] 1.2 [0.5–2.7] 0.643
Proteinuria (g/mol creatinine) 8.2 [6.7–10.5] 8.0 [6.7–10.3] 7.9 [6.4–10.3] 8.9 [7.0–11.4] 0.941
CC (ml/min/1.73 m2) 106 [95–117] 107 [97–118] 105 [93–117] 104 [93–115] 0.209
Vascular function
Systolic blood pressure (mmHg) 116 [109–124] 114 [108–123] 116 [109–124] 117 [109–125] 0.784
Diastolic blood pressure (mmHg) 73 [68–78] 72 [67–78] 74 [67–80] 73 [68–77] 0.725
Hypertension 98/559 (18%) 35/185 (19%) 25/170 (15%) 38/204 (19%) 0.716
Pulse pressure 43 [39–49] 43 [39–48] 43 [39–49] 44 [38–49] 0.971
Stroke volume/pulse pressure 1.64 [1.43–1.95] 1.68 [1.43–2.02] 1.63 [1.43–1.89] 1.63 [1.43–1.96] 0.783
Metabolic syndrome 82/560 (15%) 26/185 (14%) 21/171 (12%) 35/204 (17%) 0.321
Hyperinsulinemia 295/560 (53%) 98/185 (53%) 91/172 (53%) 106/203 (52%) 0.720
Obesity 124/564 (22%) 42/186 (23%) 34/173 (20%) 48/205 (23%) 0.265
Dyslipidaemia 109/563 (19%) 34/186 (18%) 33/173 (19%) 42/204 (21%) 0.956
Albuminuria or proteinuria 121/544 (22%) 31/178 (17%) 32/168 (19%) 58/203 (29%) 0.061
cc, creatinine clearance; LVM, left ventricular mass.
Data are presented as mean (standard deviation), median [interquartile range] or number/valid measurements (percentage in group).
*P-value indicates trend based on regression analysis with pregnancy prolongation (days) used as a continuous variable.
Table 3. Association between pregnancy prolongation after pre-eclampsia diagnosis (per day prolongation) and maternal cardiovascular, renal
and metabolic function
OR (95% CI) P-value Adjusted OR (95% CI) P-value
Cardiac parameters
Left ventricular mass index >95 g/m2 1.005 (0.956–1.056) 0.853 0.987 (0.928–1.050) 0.677
Relative wall thickness >0.42 1.023 (0.971–1.078) 0.398 1.001 (0.932–1.074) 0.987
Ejection fraction <55% 0.956 (0.873–1.047) 0.333 0.931 (0.840–1.031) 0.170
Renal parameters
Albuminuria >2.5 g/mol creatinine* 1.022 (1.005–1.040) 0.011 1.025 (1.006–1.045) 0.010
Proteinuria >30 g/mol creatinine* 0.998 (0.932–1.069) 0.995 0.994 (0.924–1.071) 0.994
Creatinine clearance <90 ml/min/1.73 m2 1.011 (0.993–1.029) 0.234 1.001 (0.981–1.022) 0.904
Annual monitoring necessary according to KDIGO* 1.013 (0.995–1.031) 0.173 1.013 (0.993–1.034) 0.211
Metabolic syndrome* 1.012 (0.993–1.032) 0.228 1.014 (0.993–1.036) 0.182
Hyperinsulinemia* 0.998 (0.984–1.012) 0.774 1.005 (0.988–1.023) 0.540
Obesity* 1.005 (0.989–1.022) 0.534 1.008 (0.988–1.028) 0.450
Dyslipidaemia* 1.003 (0.985–1.021) 0.755 0.996 (0.975–1.017) 0.702
Hypertension* 1.004 (0.986–1.023) 0.653 1.010 (0.989–1.032) 0.339
Albuminuria or proteinuria* 1.021 (1.004–1.039) 0.014 1.024 (1.005–1.044) 0.015
KDIGO, Kidney Disease Improving Global Outcomes.
ORs are adjusted for months between delivery and postpartum assessment.
aORs are adjusted for gestational age at delivery, maternal age, year of postpartum assessment, hyperinsulinemia, hypertension, obesity,
dyslipidaemia, and moderately increased albuminuria, or severely increased proteinuria.
*Not adjusted for specific metabolic syndrome component(s).
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treatment goals during pregnancy is lacking. Therefore, we
are not able to evaluate the effect of specific treatment on
pregnancy prolongation and outcomes. In addition, as we
do not have detailed information on the maternal condi-
tion that contributed to the physicians’ decision to termi-
nate pregnancy, it could be possible that immediate
scheduled birth was planned because of rapid deterioration
of maternal condition. This would mitigate the association
between pregnancy prolongation and maternal outcomes.
On the other hand, pregnancy prolongation might be asso-
ciated with more advanced maternal disease contributing
to residual albuminuria postpartum. However, the decision
to end pregnancy is often not based on increase or magni-
tude of proteinuria, as this does not affect maternal or
perinatal outcome.24 Lastly, as women had to attend the
postpartum evaluation, we were not able to assess maternal
death as outcome of a temporising management plan.
Although absolute numbers of maternal deaths are low,
and most maternal deaths occur after 34 weeks of preg-
nancy, postponing delivery in early-onset pre-eclampsia
exposes the women to increased risk of mortality.25,26
Interpretation
In pre-eclampsia diagnosed before 34 weeks’ gestation,
immediate induction of labour increases the risk of neona-
tal mortality and morbidity, and pregnancy prolongation is
preferred as long as maternal and fetal condition per-
mits.27,28 In our sample, pregnancy was prolonged for 10
days, which is slightly longer than in other studies despite
the relatively high incidence of HELLP syndrome.28–30
Women whose pregnancy was prolonged the longest, had
earlier onset of pre-eclampsia, which probably explains the
observed neonatal health gain of postponing delivery. Clini-
cians are more likely to take the risk of short-term mater-
nal and fetal complications when the survival rate of the
neonate is expected to be considerably improved with preg-
nancy prolongation.31 Deferred delivery was associated with
a decreased risk of infant mortality and resulted in higher
absolute birthweight, which in turn also contributes to an
increased survival rate.32 The presumption that the in utero
environment may be suboptimal for the growth potential
of the fetus could not be substantiated by our observations,
as the relative birthweight did not deteriorate with pro-
longed pregnancy.33,34
Prevalence of hypertension and blood pressure levels did
not relate to pregnancy prolongation, nor did estimates of
arterial compliance. The reason might be that clinical pre-
eclampsia does not induce persistent vascular alterations, or
that this contribution is minor compared with disease evolu-
tion prior to diagnosis. The changes in cardiac geometry dur-
ing normotensive pregnancy generally recover in the
postpartum period.35 In contrast, after preterm pre-eclamp-
sia, about half of women show asymptomatic structurally
altered cardiac geometrics consisting mainly of concentric
left ventricular remodelling, even after several years.4 Con-
centric remodelling is known for its association with
increased myocardial fibrosis, which decreases left ventricular
compliance and consequently impairs diastolic function.4,36
About a quarter of women in our population had a left ven-
tricle mass index >80 g/m2, which is above the upper limit of
non-pregnant reference values.37 In addition, the RWT of
our women was comparable to other formerly pre-eclamptic
women, being substantially higher than the postpartum
RWT in women with uncomplicated pregnancies.38 There
was no association between pregnancy prolongation and
deviant cardiac geometric indices and prevalence of global
left ventricular dysfunction. A possible explanation could be
that the known association with unfavourable structural
alteration in pre-eclampsia may have already occurred by the
time the diagnosis was made. A meta-analysis showed that
the steepest change in left ventricular remodelling occurs
before 30 weeks.37 Moreover, when pre-eclampsia is diag-
nosed, blood pressure-lowering medication is initiated,
which may temper further geometrical changes and myocar-
dial damage.39 It is also conceivable that the time-span of
estimated disease prolongation is too short to result in dele-
terious effects on cardiac geometry.
The median albumin-to-creatinine ratio in our popula-
tion was 1.0 g/mol (0.5–2.3 g/mol), which is slightly higher
than the normal range in healthy women aged between 20
and 40 years (0.7 g/mol to 0.4–1.1 g/mol).40 Pre-eclamptic
women with prolonged pregnancy have a slightly higher
risk of residual moderately increased albuminuria postpar-
tum, but glomerular filtration rate and serum creatinine
level were not affected. Also, pregnancy prolongation did
not increase the prevalence of severely increased protein-
uria, which usually resolves within weeks to months post-
partum.15 These observations suggest a higher risk on
moderate endothelial dysfunction when a policy of preg-
nancy prolongation is pursued. It is uncertain whether resid-
ual albuminuria reflects incomplete recovery from
permanent damage incurred during pregnancy or undetected
pre-existing endothelial dysfunction predisposing to pre-
eclampsia and postpartum diagnosis of albuminuria.41,42
Pre-eclampsia is associated with an upregulation of placental
sFlt-1, which scavenges vascular endothelial growth factor
(VEGF). Reduction of VEGF in mice results in proteinuria
and glomerular endotheliosis, resembling pre-eclampsia.43
VEGF is a signal protein produced by podocytes with auto-
crine function to support cell survival, and paracrine func-
tion on the glomerular endothelial cells.44 The degree of
damaged podocytes correlates with the intensity of protein-
uria, and depletion up to 20% results in a transient increase
in proteinuria, with preserved creatinine clearance.45
Proteinuria itself is potentially harmful to the proximal
tubule and podocytes, as proteins in the glomerular
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ultrafiltrate activate inflammation and fibrosis, and the pres-
ence of proteins impairs podocyte regeneration.46,47
Our results emphasise the importance of monitoring the
presence of moderately increased albuminuria in women
with early-onset pre-eclampsia, especially in women whose
pregnancy is prolonged by several weeks. To date, no specific
interventions to improve long-term outcomes are evidenced,
but adequate blood pressure control in hypertension, lifestyle
and exercise advise might lower albuminuria in screen-
positive women.48,49
Postpartum metabolic syndrome was observed in 15% of
women in our population, compared with a prevalence of
5% in Dutch women of similar age.50 Prevalence was not
related to duration of preeclampsia – nor were the individ-
ual components of the metabolic syndrome other than
albuminuria. Similar results were found in women with
gestational hypertensive disorders at term whose induction
of labour was postponed for a week compared with imme-
diate delivery.14 As hypertensive complications during preg-
nancy are associated with exaggerated metabolic changes
prior to overt clinical disease, it might be unlikely that
duration of pre-eclampsia affects the development of meta-
bolic syndrome postpartum.51–53 These findings support
the concept of Romundstad et al. who suggested that post-
partum development of metabolic syndrome is attributable
to shared pre-pregnancy risk factors rather than a direct
influence of gestational hypertensive disorders.7
Conclusion
Prolongation of pregnancy in early-onset pre-eclampsia
with consideration of individual context at the discretion
of the attending obstetrician relates to reduced infant mor-
tality. Moreover, it is associated with a raised prevalence of
moderately increased albuminuria but does not seem to
have an adverse effect on cardiovascular function or meta-
bolic status. It is unknown how these findings translate to
long-term cardiovascular morbidity. Our findings should
also be evaluated in a setting with detailed information on
disease severity at presentation and peripartum manage-
ment.
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